x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DCL-001227
| Product Information | |
|---|---|
| Organism | Rat |
| Tissue | Pancreatic islets |
| Cell Type | Epithelial cells |
| Karyotype | Modal chromosome number 66 up to passage 50 |
| Product Description | BRIN-BG7 is a hybrid cell line formed by the electrofusion of a primary culture of NEDH rat pancreatic islets with RINm5F (a cell line derived from a NEDH rat insuliinoma). BRIN-BG7 has been shown to be tumourigenic when transplanted into a SCID mouse host. BRIN-BG7 has been mycoplasma eradicated and the stocks available for supply have undergone a further 10 passages without detection of mycoplasma. The cell line has applications in the study of pancreatic beta cell function. |
| Format | Frozen |
| Growth Properties | Adherent |
| Shipping & Storage | |
|---|---|
| Shipping | Cryopreserved on dry ice. |
| Storage Instructions | Split sub-confluent cultures (70-80%) 1:2 to 1:6 i.e. seeding at 2-4 x 104 cells/cm2 using 0.05% trypsin or trypsin/EDTA; 5% CO2; 37 °C. Population doubling approx 20hrs. At confluence 105 cells/cm2 can be expected. |
| Storage Buffer/Media | RPMI-1640 + 2mM Glutamine + 10% FCS |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
